Skip to content

Application and effectiveness evaluation of the "hospital community home" integrated pulmonary rehabilitation standardized management plan for COPD patients based on IoT technology

Application and effectiveness evaluation of the "hospital community home" integrated pulmonary rehabilitation standardized management plan for COPD patients based on IoT technology

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092556
Enrollment
Unknown
Registered
2024-11-19
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Pulmonary rehabilitation exercise group:Implementation of hospital community home pulmonary rehabilitation program for COPD patients based on IoT technology
Conventional treatment group:Routine discharge management

Sponsors

Changsha Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 35-80 years who meet the diagnosis of chronic obstructive pulmonary disease; (2) The usual place of residence is residents of urban areas such as Changsha, Wangcheng, Liuyang, and Ningxiang; (3) On the day of enrollment, the pulmonary function report showed that after inhaling bronchodilators (15-30 minutes after inhaling 400 µ g of salbutamol), the FEV1/FVC was less than 0.70, and the percentage of FEV1 to the expected value was between 30% and 80% (i.e. GOLD grade 2-3); (4) Has experienced 2 or more moderate acute exacerbations or 1 or more severe acute exacerbations within the past 12 months, supported by clinical medical records; (5) No acute exacerbation has occurred within 4 consecutive weeks; (6) Sign the informed consent form, understand and actively cooperate with the follow-up work.

Exclusion criteria

Exclusion criteria: (1) Merge important diseases other than chronic obstructive pulmonary disease; (2) Patients with significant clinical abnormalities in laboratory tests; (3) Merge clinically significant restrictive ventilation dysfunction diseases such as pneumoconiosis; (4) Merge untreated or advanced malignant tumors; (5) Merge active pulmonary tuberculosis; (6) Patients with life-threatening pulmonary embolism, clinically significant alpha 1-antitrypsin deficiency, or cystic fibrosis; (7) History of lobectomy; (8) Lower limb mobility impairment, unable to complete the six minute walking test assessment alone; (9) Complies with absolute contraindications for pulmonary function tests; (10) Have participated in other respiratory clinical trials within the past 3 months prior to screening; (11) Researchers believe that patients who are not suitable to participate in clinical studies.

Design outcomes

Primary

MeasureTime frame
Frequency of moderate to severe acute exacerbation of chronic obstructive pulmonary disease;Maximal Inspiratory Pressure,MIP;Six-Minute-Walk-Distance,6MWD;modified British Medical Research Council,mMRC;Pulmonary function;

Secondary

MeasureTime frame
Home oxygen therapy time;Non invasive ventilation time at night;Adverse events related to rehabilitation therapy;COPD related treatment costs;Compliance;Satisfaction ;

Countries

China

Contacts

Public ContactDa Liu

Changsha Central Hospital

2018050679@usc.edu.cn+86 176 0731 8128

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026